References:
1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing
Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From
the Women’s Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33.
2. Malet C, Spritzer P, Guillaumin D, Kuttenn F. Progesterone effect on cellgrowth, ultrastructural aspect and estradiol receptors of normal human breast
epithelial (HBE) cells in culture. J Steroid Biochem Mol Biol. 2000Jun;73(3-4):171-81.
3. Mauvais-Jarvis P, Kuttenn F, Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat. 1986;8(3):179-88.
4. Söderqvist G, von Schoultz B, Tani E, Skoog L. Estrogen and progesteronereceptor content in breast epithelial cells from healthy women during the
menstrual cycle. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):874-9.
5. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S,Barrett-Connor E. Symptom relief and side effects of postmenopausal hormones:results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998 Dec;92(6):982-8.
6. Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol. 1989 Apr;73(4):606-12.
7. de Lignières B. Effects of progestogens on the postmenopausal breast. Climacteric. 2002;5(3):229–235.
8. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat. 2007;101(2):125–134.
9. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998;69(5):963–969.
10. Groshong SD, Owen GI, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin- dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997;11(11):1593–1607.
11. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448–454.
12. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199–208.
13. Wagner JD; Martino MA; Jayo MJ; Anthony MS; Clarkson TB; Cefalu WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically post- menopausal cynomolgus monkeys. Metabolism 1996 Oct;45(10):1254-62.
14. Elkind-Hirsch KE; Sherman LD; Malinak R. Hor- mone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 1993 Feb;76(2):472-5.
15. de Lignieres B. Oral micronized progesterone. Clin Ther 1999. jan;21(1):41-60.
16. Godsland IF; Gangar K; Walton C; Cust MP; Whitehead MI; Wynn V; Stevenson JC. Insulin resis- tance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone re- placement therapy. Metabolism 1993 Jul;42(7):846-53.
17. Minshall RD, Stanczyk FZ, Miyagawa K, et al. Ovarian steroid protec- tion against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab. 1998;83(2):649–659.
18. Mishra RG, Hermsmeyer RK, Miyagawas K, et al. Medroxy- progesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys. J Clin Endocrinol Metab. 2005;90(6):3706–3714.
19. Miyagawa K, Roöch J, Stanczyk F, Hermsmeyer K. Medroxypro- gesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3(3):324–327.
20. Otsuki M; Saito H; Xu X; Sumitani S; Kouhara H; Kishimoto T; Kasayama S. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001 Feb;21(2):243-8.
21. Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT. The effects of hormone replacement therapy on carbohy- drate metabolism and cardiovascular risk factors in surgically postmeno- pausal cynomolgus monkeys. Metabolism. 1996;45(10):1254–1262.
22. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized mon- keys. Lack of an effect of added progesterone. Arteriosclerosis. 1990;10(6):1051–1057.
23. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol. 1998;18(7):1164–1171.
24. Clarkson TB. Progestogens and cardiovascu-
lar disease. A critical review. J Reprod Med 1999 Feb;44(2 Suppl):180-4.
25. Fitzpatrick LA, Pace C, Witta B. Comparison of regimens containingoral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med. 2000;9(4):381–387.
26. Baulieu E, Schumacher M. Progesterone as a neuroactive neurosteroid, withspecial reference to the effect of progesterone on myelination. Steroids. 2000
Oct-Nov;65(10-11):605-12.
27. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL,Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S,
Wactawski-Wende J; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28;289(20):2651-62.
28. Zhang F; Chen Y; Pisha E; Shen L; Xiong Y; van Breemen RB; Bolton JL. The major metabolite of eq- uilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hy- droxyequilenin-o-quinone. Chem Res Toxicol 1999 Feb;12(2):204-13.
29. Pisha E; Lui X; Constantinou AI; Bolton JL Evidence that a metabolite of equine estrogens, 4- hydroxyequilenin, induces cellular transformation in vitro. Chem Res Toxicol 2001 Jan;14(1):82-90.
30. Melamed M, Castaño E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol. 1997;11(12):1868–1878.
31. Scarabin PY; Alhenc-Gelas M; Plu-Bureau G; Taisne P; Agher R; Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial Arterioscler Thromb Vasc Biol 1997 Nov;17(11):3071-8.
32. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
33. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573–1580.
34. Feeman WE Jr. Thrombotic stroke in an otherwise healthy middle- aged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. J Gend Specif Med. 2000;3(8):62–64.
35. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
36. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives contain norgestimate and 35 ìg of ethinyl estradiol. Contraception. 2006;73(3):223–228.
37. Thompson v Western States, 122 S C5 1497, 1505 (2002).
38. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006 May 8;166(9):1021-6.